.png){kind=icon}
.png){kind=icon}
Return
Extended-Release Calcifediol Identifies a Therapeutic Vitamin D Range in Chronic Kidney Disease stage 3-4
.png){kind=icon}
OA
AI
J
A
C
DOI：10.1093/ckj/sfag194.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease (CKD) driven by dysregulated vitamin D metabolism. The serum 25-hydroxyvitamin D (25D) levels required for targeted intact parathyroid hormone (iPTH) reductions are poorly defined, and conventional sufficiency thresholds of 20 or 30 ng/mL are inadequate. Exposure–response (E–R) modeling was used to define a 25D range associated with a 30% iPTH reduction during treatment with extended-release calcifediol (ERC).
Journal
IF:
4.6
Papers:
2.9K
Citations:
7.1K
Organization
Cited Papers